Search results
Median overall survival was 9.9 years (95% CI 7.9–11.9). Patients without recurrence had longer survival than patients with one or more recurrences. Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years.
Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9-11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours.
4 paź 2024 · Younger patients with good health at diagnosis and those with favorable tumor genetics (MGMT promoter methylation and IDH mutations, specifically) tend to survive longer.
19 lut 2009 · Patients with a glioblastoma carrying an IDH1 or IDH2 mutation had a median overall survival of 31 months, which was significantly longer than the 15-month survival in patients with wild-type...
We retrospectively analyzed 120 IDH-wildtype glioblastomas operated on at our institution between 2013 and 2018. We divided them into LTS patients, surviving more than 3 years, and non-LTS patients, and then compared their features. Additionally, we performed DNA methylation-based brain tumor classification in LTS patients.
We suggest that glioblastoma patients with a combination of favorable prognostic factors can achieve LTS in 74% of cases. In addition, methylome analysis is important to ascertain the type of glioma in LTS patients, especially when the MGMT promoter is unmethylated.
24 paź 2023 · The classification estimates median survival in three subgroups: RPA class III (age < 50 years, KPS ≥ 90), 17.1 months (12-month survival 70%); RPA class IV (age <50, KPS <90), 11.2 months (12-month survival 46%); and RPA class V (all others), 7.5 months (12-month survival 28%).
